Ubi Titer Issue #1
Bispecific ADCs and T-Cell Engagers in Solid Tumors
Bispecific formats — ADCs, TCEs, and targeted delivery — converging on solid tumor antigen heterogeneity as the defining challenge of 2026
- bispecific antibodies
- antibody-drug conjugates
- T-cell engagers
- VHH
- nanobodies
- solid tumors
What this issue covers
- 1.Development of Antibody-Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer
ADCs targeting L1CAM — a marker of metastasis-initiating stem cells — achieve complete tumor regression and 100% survival in PDX lung metastasis models at 1 mg/kg with a non-cleavable linker to PNU-159682.
- 2.Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer
Bispecific ADC simultaneously targeting B7-H3 and PSMA outperforms single-target ADCs in prostate cancer CDX/PDX models by exploiting bystander killing and dual-antigen redundancy against heterogeneous tumors. FDA IND cleared.
- 3.A Unified Dataset for Antibody and Nanobody Design Including Sequence, Structure, and Binding Affinity Data
ANDD: 48,683 antibody/nanobody sequences, 24,941 structures, 9,557 affinity values unified from 15 sources — including 30,119 VHH entries. Largest integrated Ab/Nb design dataset with provenance-tracked affinity data.
- 4.NbBayesLM: bayesian prediction of nanobody thermostability using protein language model
ESM-2 embeddings + physicochemical Bayesian priors predict nanobody Tm with calibrated confidence intervals. Outperforms point-estimate PLMs and classical feature models. CDR-level attribution identifies instability hotspots.
- 5.Adaptive Disorder as the Hallmark of Nanobodies Antigen-Binding Loops
MD simulations show nanobody CDR3 loops are intrinsically disordered in solution — not just flexible. Adaptive disorder enables binding to concave epitopes. CDR1/2 are rigid anchors; CDR3 is a conformationally malleable binding arm.
- 6.A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
VHH-based bispecific T cell engager co-engaging oncofetal antigen 5T4 and Vδ2-TCR kills solid tumor cells in patient-derived 3D models without cytotoxicity against healthy 5T4-expressing tissue.
Paper 1 · Molecular Cancer Therapeutics
Development of Antibody-Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer
ADCs targeting L1CAM — a marker of metastasis-initiating stem cells — achieve complete tumor regression and 100% survival in PDX lung metastasis models at 1 mg/kg with a non-cleavable linker to PNU-159682.
Core finding
Three L1CAM-targeting antibodies were developed against the Ig-like and FNIII domains of the L1CAM extracellular region, then conjugated to PNU-159682 (nemorubicin metabolite) via a ThioBridge disulfide-rebridging platform with non-cleavable tri-glycine linker at DAR=4. In lung metastasis models of TNBC and LUAD (including two PDX lines), four weekly doses of 1 mg/kg completely eradicated detectable disease, with animals surviving >9 months without relapse. L1CAM knockdown abolished efficacy, confirming on-target mechanism.
What is novel
L1CAM is the first ADC target specifically chosen to eliminate metastasis stem cells (MetSCs) rather than the bulk tumor. Prior L1CAM antibodies failed clinically due to lack of cytotoxic mechanism; the ADC format leverages L1CAM's high intrinsic internalization rate to deliver payload selectively to the MetSC compartment that survives standard therapy. The non-cleavable linker outperforming the cleavable format is a mechanistically interesting finding suggesting cathepsin activity limitations in the lung tumor microenvironment.
Limitations
Purely preclinical. L1CAM is expressed in peripheral neuronal tissue and kidney tubules, raising off-target safety concerns that will require careful NHP toxicology. Therapeutic window was assessed only in mice using a mouse-cross-reactive antibody; extrapolation to humans needs NHP confirmation. L1CAM expression varies widely even within histological subtypes.
Why it matters in context
Metastasis stem cells have long been proposed as the key therapeutic target for preventing relapse, but the field has lacked a validated surface marker with sufficient tumor-to-normal selectivity. The Massagué group's prior work establishing L1CAM as a pan-cancer MetSC marker (Nature Cancer 2019) laid the groundwork for this ADC approach. This study provides the first proof-of-concept that pharmacological elimination of L1CAM+ cells translates to durable metastatic control — a conceptual advance as significant as the specific molecule.
Paper 2 · Molecular Cancer Therapeutics
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer
Bispecific ADC simultaneously targeting B7-H3 and PSMA outperforms single-target ADCs in prostate cancer CDX/PDX models by exploiting bystander killing and dual-antigen redundancy against heterogeneous tumors. FDA IND cleared.
Core finding
GenSci143 combines a bispecific antibody targeting B7-H3 and PSMA with a TOP1 inhibitor payload via a plasma-stable linker. B7-H3 and PSMA are highly co-expressed in prostate cancer (confirmed by gene profiling). In vitro potency was maintained even in cells expressing only one target, and bystander killing extended activity to antigen-negative bystander cells. In CDX/PDX models of mCRPC, GenSci143 induced superior tumor regression versus single-target B7-H3 and PSMA benchmark ADCs. NHP PK studies confirmed favorable plasma stability.
What is novel
Bispecific ADCs represent a new structural class — the antibody component is bispecific rather than monospecific — specifically designed to address tumor antigen heterogeneity, a persistent cause of ADC resistance. GenSci143 is one of the first BsADCs to enter IND-stage development, validating the concept as a clinically viable strategy rather than a theoretical exercise.
Limitations
Industry-sponsored study with potential for positive result bias. Preclinical only — no Phase I pharmacokinetics or tolerability data in humans yet. The PSMA ADC space is crowded with clinical-stage programs; differentiation of bispecific format vs. monospecific PSMA-ADC needs clinical validation. Prostate cancer antigen heterogeneity may be more complex than two-antigen targeting can address.
Why it matters in context
Tumor antigen heterogeneity — where a subset of cancer cells downregulate the ADC's target antigen — is increasingly recognized as a primary mechanism of ADC resistance. The field is pursuing three strategies: bystander killing payloads (membrane-permeable, already in approved ADCs), bispecific antibodies (two tumor targets, one ADC), and dual-payload formats. GenSci143 exemplifies the bispecific approach, and the near-simultaneous emergence of DXC014 (a competing B7-H3×PSMA BsADC) strongly validates the target combination.
Paper 3 · Scientific Data
A Unified Dataset for Antibody and Nanobody Design Including Sequence, Structure, and Binding Affinity Data
ANDD: 48,683 antibody/nanobody sequences, 24,941 structures, 9,557 affinity values unified from 15 sources — including 30,119 VHH entries. Largest integrated Ab/Nb design dataset with provenance-tracked affinity data.
Core finding
ANDD integrates 15 public sources into a single quality-controlled dataset of 48,683 antibody and nanobody sequences with structural data for 24,941 entries, antigen sequences for 12,575 entries, and 9,557 affinity values — the largest integrated collection to date. The VHH/nanobody slice alone covers 30,119 entries. A standardized format with explicit provenance tags resolves the format inconsistency that has fragmented antibody ML datasets across OAS, PDB, SAbDab, and smaller databases.
What is novel
First resource to systematically combine sequence, structure, antigen context, and experimentally-grounded binding affinity for both conventional antibodies and VHH nanobodies in a unified, quality-controlled dataset. The affinity coverage — augmented with ANTIPASTI predictions where experimental data was absent, with clear flags — is the largest single Ab/Nb affinity collection assembled.
Limitations
A substantial fraction of affinity values are ANTIPASTI-predicted rather than experimental, which is useful for training but not a substitute for measured Kd/IC50 in validation contexts. Dataset covers static sequence and structure; conformational ensemble data is absent.
Why it matters in context
Benchmark fragmentation has been a persistent complaint in the computational antibody design community — cross-model comparison is confounded when each method uses different training/test splits from different databases. ANDD is the first resource credible enough to serve as a community benchmark. The Zenodo release (records/16894086) makes direct download accessible.
Paper 4 · Frontiers in Bioinformatics
NbBayesLM: bayesian prediction of nanobody thermostability using protein language model
ESM-2 embeddings + physicochemical Bayesian priors predict nanobody Tm with calibrated confidence intervals. Outperforms point-estimate PLMs and classical feature models. CDR-level attribution identifies instability hotspots.
Core finding
NbBayesLM wraps ESM-2 protein language model embeddings in a Bayesian neural network where physicochemical amino acid properties serve as prior distributions over model weights rather than fixed input features. On nanobody melting temperature prediction, this outperforms point-estimate PLMs and classical feature-only models while producing calibrated uncertainty estimates that tell engineers when a prediction should not be trusted.
What is novel
First Bayesian neural network specifically for nanobody thermostability prediction that produces calibrated confidence intervals rather than point estimates. Using physicochemical properties as Bayesian priors — rather than concatenated features — is a principled integration of domain knowledge with learned representations that improves both accuracy and calibration simultaneously.
Limitations
Performance on nanobodies outside the camelid VHH scaffold is not evaluated. Training set size in nanobody Tm data is limited, which may inflate cross-validation performance. CDR attribution is sequence-based; structural context is not integrated.
Why it matters in context
Computational nanobody stability prediction has been approached by fine-tuned PLMs, biophysical feature models, and graph neural networks. NbBayesLM's addition of calibrated uncertainty addresses the decision-making gap: the confidence interval tells engineers when to trust a prediction, not just what it says.
Paper 5 · Journal of Chemical Information and Modeling
Adaptive Disorder as the Hallmark of Nanobodies Antigen-Binding Loops
MD simulations show nanobody CDR3 loops are intrinsically disordered in solution — not just flexible. Adaptive disorder enables binding to concave epitopes. CDR1/2 are rigid anchors; CDR3 is a conformationally malleable binding arm.
Core finding
Molecular dynamics simulations across a diverse nanobody panel show CDR3 loops are intrinsically disordered in solution — sampling multiple conformations before committing to a bound state upon epitope contact. CDR1 and CDR2 act as relatively rigid structural anchors while CDR3 mediates binding through adaptive disorder. The longer CDR3 loops characteristic of VHH are selected because disorder enables access to concave epitopes that rigid loops cannot reach.
What is novel
First systematic characterization of CDR3 intrinsic disorder across a diverse nanobody panel using MD simulations. Reframes CDR3 conformational freedom as an adaptive feature rather than a structural liability, with direct implications for computational nanobody design tools that model CDRs as single energy-minimized conformations.
Limitations
MD simulation timescales may not fully sample the slow conformational dynamics of longer CDR3 loops. Panel diversity may not capture the full range of therapeutic VHH CDR3 lengths. Experimental validation of disorder-to-order transitions in binding kinetics is not provided.
Why it matters in context
The field has known nanobody CDR3 loops are longer and more variable than conventional VH CDR3, but the functional interpretation has been debated. This paper establishes adaptive disorder as the structural logic behind unique epitope access, positioning nanobody design tools to incorporate ensemble-based CDR3 scoring.
Paper 6 · Clinical Immunology
A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies
VHH-based bispecific T cell engager co-engaging oncofetal antigen 5T4 and Vδ2-TCR kills solid tumor cells in patient-derived 3D models without cytotoxicity against healthy 5T4-expressing tissue.
Core finding
High-affinity 5T4-specific VHHs were linked to a Vδ2-TCR-specific VHH to generate a bispecific T cell engager. In 2D and 3D patient-derived tumor models across multiple solid malignancy types, the bsTCE triggered strong Vγ9Vδ2-T cell cytokine production and tumor lysis. When tested against healthy tissues expressing 5T4 at physiological (low) levels, cytotoxicity was not observed — demonstrating that the oncofetal upregulation of 5T4 provides a functional tumor-selectivity window.
What is novel
Combining an oncofetal antigen (5T4) with gamma-delta T cell recruitment is a strategically elegant approach to the toxicity problem that has stalled solid tumor bispecific T cell engagers. Previous Lava Therapeutics work used this gamma-delta platform for hematological malignancies; this extends it to solid tumors via a target antigen expressed preferentially on malignant cells.
Limitations
Preclinical study only. Vγ9Vδ2-T cells constitute roughly 1-5% of peripheral blood T cells and their frequency and function vary significantly across patients. No clinical data available. The 5T4 expression landscape across solid malignancy subtypes requires full characterization before patient selection criteria can be established.
Why it matters in context
Solid tumor bispecific T cell engagers have faced persistent challenges from on-target off-tumor toxicity and poor tumor penetration. The field is responding with two strategies: tumor-preferential targets (5T4, here) and alternative T cell subsets (gamma-delta T cells, innate-like with lower activation thresholds). This paper is one of several recent studies exploring whether gamma-delta T cells can overcome the limitations of conventional CD3-redirecting bispecifics in solid tumors.
Primary papers
- [1] Development of Antibody-Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer (Molecular Cancer Therapeutics)
- [2] Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer (Molecular Cancer Therapeutics)
- [3] A Unified Dataset for Antibody and Nanobody Design Including Sequence, Structure, and Binding Affinity Data (Scientific Data)
- [4] NbBayesLM: bayesian prediction of nanobody thermostability using protein language model (Frontiers in Bioinformatics)
- [5] Adaptive Disorder as the Hallmark of Nanobodies Antigen-Binding Loops (Journal of Chemical Information and Modeling)
- [6] A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies (Clinical Immunology)